Company intelligence / Profile preview

Manresana de Micobacteriologia, S.L.

Ownership: Private
Development stage: Commercial

Overview

The company develops Nyaditum resae®, a natural probiotic technology aimed at protecting against tuberculosis. It was founded as a spin-off from IGTP by Dr. Pere-Joan Cardona Iglesias and focuses on innovative approaches to prevent active TB through modulation of the microbiome using probiotics. Clinical results are not detailed in public sources; the product appears to be in development rather than fully commercialized.[1][2][3]

Therapeutic areas: Infectious Diseases
Modalities: Probiotics
Industry: Biotech

Drug pipeline

1 asset

Nyaditum resae

Commercial

Indications: Tuberculosis

Partnerships

Spin-off from Institut Germans Trias i Pujol (IGTP); no major pharma partnerships listed[2]

Beyond the preview

Go deeper on Manresana de Micobacteriologia, S.L..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Manresana de Micobacteriologia, S.L..

Explore the full profile